Mab Designs announces publication of C20, a selective inhibitor of IL-6 trans-signalling, in Nature's Communications Biology

Contributed by: GlobeNewswire

Tags

Antibodies

More Like This

Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

PR Newswire associated0

ImmunAbs Announces Conclusion of Phase 1 Clinical Trial, Revealing Positive Topline Results

IGI Announces Publication in Nature Cancer on ISB 2001, IGI's Innovative Trispecific Antibody for Relapsed/Refractory Multiple Myeloma

Merus Announces the Journal Publication of Petosemtamab Mechanism of Action

Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreated Multiple Myeloma

Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003 (anti-CD40 mAb) Phase I Trial at ESMO 2023

JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)